Annotation Detail
Information
- Associated Genes
- IDH1
- Associated Variants
-
IDH1 R132
IDH1 R132 - Associated Disease
- high grade glioma
- Source Database
- CIViC Evidence
- Description
- In a clinical study of 63 recurrent glioma patients, patients treated with bevacizumab monotherapy (n=11) and harboring IDH1 codon 132 mutation were associated with improved progression free survival (3.23 months vs. 1.37 months, P=0.05), as compared to patients with wild-type IDH1.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/2330
- Gene URL
- https://civic.genome.wustl.edu/links/genes/26
- Variant URL
- https://civic.genome.wustl.edu/links/variants/58
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Malignant Glioma
- Evidence Direction
- Supports
- Drug
- Bevacizumab
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 22199315
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Bevacizumab | Sensitivity | true |